Eff ectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Aharona Glatman-Freedman, Yael Hershkovitz, Zalman Kaufman, Rita Dichtiar, Lital Keinan-Boker, Michal Bromberg

Research output: Contribution to journalArticlepeer-review

Abstract

In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.

Original languageEnglish
Pages (from-to)2919-2922
Number of pages4
JournalEmerging Infectious Diseases
Volume27
Issue number11
DOIs
StatePublished - Nov 2021

Fingerprint

Dive into the research topics of 'Eff ectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021'. Together they form a unique fingerprint.

Cite this